Last updated: April 24, 2026
Who supplies nimodipine APIs globally?
Nimodipine (CAS 66085-60-5) is supplied by multiple global API manufacturers and intermediate specialists, typically under GMP and DMF/CEP pathways depending on destination market. The most visible supplier set by market presence and export activity is concentrated in India and China, with additional EU and Japan-origin sources for finished dosage.
Representative supplier footprint (API / intermediate-focused manufacturers)
- India: Lupin (API manufacturing footprint for multiple cardiovascular products including calcium channel blockers), Zydus (API manufacturing footprint), Sun Pharma (API manufacturing footprint)
- China: multiple nimodipine API and related ester/intermediate suppliers serving contract manufacturing and export channels
- EU / Japan (niche, via finished products more than API): suppliers tied to brand/market-authorized products
Market reality for diligence: nimodipine is widely sold as an API and as an intermediate-driven active, but supplier access depends on whether the buyer needs (1) a DMF/CEP-enabled API, (2) DMF-holder status, or (3) only COA-lot trade supply.
Which companies supply nimodipine finished dosage products (market-authorized tablets/capsules)?
Finished-dose supply is dominated by brand and generic players with regulatory submissions in EU, UK, US, India, and parts of MENA/APAC. The practical path for many buyers is to source from finished-dose manufacturers with established local registrations, then move upstream only if required for cost or supply continuity.
Typical finished-dose supplier pattern
- EU/UK: generic manufacturers that file and maintain MA/PL and batch release locally
- US: holders of ANDAs for oral nimodipine, with manufacturing tied to US-registered sites
- India: generic brands with both domestic and export approvals
- MENA/APAC: local registrants relying on API imported from India/China with local packaging
What standards govern nimodipine supplier qualification?
For nimodipine API and oral finished dosage, buyers usually qualify suppliers against these requirements:
API qualification checkpoints
- GMP manufacturing site (PIC/S or equivalent)
- API documentation: DMF (US), CEP (Europe) or ASMF where used
- Analytical release: full specifications for assay, impurities, residual solvents, water content, polymorphic form where relevant
- Stability program aligned with intended shelf life
- Change control: notification and approval workflow
Finished dosage qualification checkpoints
- Marketing authorization in target geography
- CMC package support: manufacturing process, controls, validation, container closure
- Micro and dissolution controls for solid oral products
- GxP distribution: cold chain not typical for nimodipine unless specified by product insert
Where do nimodipine suppliers typically sit in the supply chain?
Supplier roles for nimodipine generally fall into two layers:
1) API producers / intermediate producers
- Sell bulk API under GMP with documentation packages
- Often support multiple dosage customers (tablet, capsule, and some combination formats)
2) Finished dosage manufacturers and registrants
- Package and release under market approvals
- Source API from contracted API producers and manage formulation-specific controls
How to shortlist nimodipine suppliers for business use
A short list usually includes suppliers that can meet documentation and compliance timelines, not only price.
Selection criteria used by procurement and regulatory teams
- Documentation readiness: DMF/CEP availability for nimodipine
- Batch consistency: impurity profile stability across lots
- Regulatory track record: site inspection history and corrective action responsiveness
- Supply reliability: lead time, min order quantity, and capacity for scale-up
- Technical support: method transfer and spec alignment for dissolution and impurities
Key supplier clusters (practical market segmentation)
- India-based API suppliers: most common for export due to DMF readiness in many API categories and scale for solid oral drugs.
- China-based API suppliers: strong cost positioning; documentation varies by producer and lot origin.
- EU/Japan suppliers: more often appear as finished-dose manufacturers in local markets than as primary API sources for open-market procurement.
What procurement outcomes typically differ by supplier type?
- API-only procurement: faster unit cost optimization but requires full internal CMC execution for formulation, stability, and regulatory filings.
- Finished-dose procurement: slower margin improvement but reduces formulation risk and speeds market entry if registrations already exist.
- Hybrid sourcing: purchase API under defined specs, then contract-fill/contract-manufacture under buyer-owned QA.
Key Takeaways
- Nimodipine supply is concentrated in India and China at API level, with EU/US presence mainly through finished-dose manufacturers tied to regulatory approvals.
- Supplier qualification should prioritize DMF/CEP readiness, GMP site inspection status, impurity profile consistency, and stability support, not price alone.
- For market entry or scale-up, procurement teams typically choose between API sourcing (requires full CMC ownership) and finished-dose sourcing (faster launch if registrations exist).
FAQs
1) Is nimodipine widely available as an API?
Yes. Nimodipine API is commercially supplied, with most availability concentrated among large-scale API producers in India and China.
2) Do nimodipine suppliers offer DMF or CEP documentation?
Many suppliers do, but it depends on the specific site and producer. Buyers typically filter suppliers based on DMF (US) or CEP/ASMF availability.
3) Is nimodipine supply mainly driven by API or finished dosage manufacturers?
API supply drives bulk procurement economics, while finished-dose manufacturers drive go-to-market speed when market authorizations already exist.
4) What technical risks matter most for nimodipine sourcing?
Impurity profile consistency, analytical method alignment, and stability support are the main risks that affect both regulatory review and batch acceptance.
5) Where should a buyer start for nimodipine sourcing in diligence?
Start with GMP-compliant API sites or finished-dose manufacturers that can provide documentation packages required by the target geography (DMF/CEP/MA support).
References
[1] European Medicines Agency (EMA). Public assessment and product information for nimodipine-containing medicinal products. https://www.ema.europa.eu/
[2] U.S. FDA. Drug Databases (Orange Book) and regulatory records for nimodipine products. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] World Health Organization (WHO). GMP and related guidance for pharmaceutical manufacturing and quality. https://www.who.int/medicines/areas/quality_safety/quality_assurance/gmp/
[4] PubChem. Nimodipine (CAS 66085-60-5) substance entry. https://pubchem.ncbi.nlm.nih.gov/
